| Hemodynamic results and changes in myocardial function after transcatheter aortic valve implantation. | |
| | |
MedLine Citation:
|
PMID: 20435207 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: This prospective study was designed to evaluate the hemodynamic results of transcatheter aortic valve implantation (TAVI) with the CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) and the effects on left ventricular function. METHODS: From June 2008 to June 2009, consecutive patients with severe symptomatic aortic valve stenosis (aortic valve area <1 cm(2)) and the indication for TAVI were included. Aortic valve prosthesis was inserted retrograde. Examinations of study patients were performed before, 30 days, and 6 months after TAVI and comprised measurement of B-type natriuretic peptide and echocardiography. Severe prosthesis-patient mismatch was defined as an indexed effective aortic valve area < or =0.65 cm(2)/m(2). RESULTS: In 39 patients, follow-up examinations were performed after TAVI. Severe prosthesis-patient mismatch seldom occurred (n = 1), but mild to moderate aortic valve regurgitation due to paravalvular leaks was common (n = 24, 62%). After 6 months, left ventricular mass index declined (158 +/- 46 vs 138 +/- 45 g/m(2), P = .001), and peak early diastolic mitral annular velocity (E') and peak systolic mitral annular velocity (S') increased (P = .004 and P < .001, respectively). B-type natriuretic peptide levels decreased (744 +/- 708 at baseline vs 367 +/- 273 at 30 days, P = .003, 279 +/- 186 pg/mL at 6 months, P = .001). Left ventricular diameters and ejection fraction remained unchanged. CONCLUSION: Despite the high incidence of paravalvular regurgitation after TAVI, hemodynamic results were favorable. Furthermore, TAVI had positive effects on left ventricular remodeling and improved neurohormonal activity, myocardial hypertrophy, and diastolic function. |
| | |
Authors:
|
Michael Gotzmann; Michael Lindstaedt; Waldemar Bojara; Andreas M?gge; Alfried Germing |
Related Documents
:
|
11169297 - Prenatal therapy of non-immunologic hydrops fetalis caused by severe aortic stenosis. 10887357 - An unusual case of acquired ventricular septal defect as a complication of aortic valve... 6973327 - Ten-year follow-up in aortic valve replacement using the björk-shiley prosthesis. 1266757 - Acute coronary embolism complicating bacterial endocarditis: operative treatment. 2806287 - Therapeutic targets and expectations for the treatment of heart failure. 9436817 - Ecto-5'-nucleotidase mediates infarct size-limiting effect by ischemic preconditioning ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American heart journal Volume: 159 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-03 Completed Date: 2010-05-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 926-32 Citation Subset: AIM; IM |
Copyright Information:
|
2010 Mosby, Inc. All rights reserved. |
Affiliation:
|
BG-Kliniken Bergmannsheil, Medical Clinic II, Ruhr-University Bochum, Germany. michael_gotzmann@web.de <michael_gotzmann@web.de> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Aortic Valve / surgery* Aortic Valve Insufficiency / epidemiology Aortic Valve Stenosis / surgery* Cardiac Volume Echocardiography, Doppler Female Heart Valve Prosthesis Heart Valve Prosthesis Implantation* Hemodynamics Humans Male Natriuretic Peptide, Brain / analysis Postoperative Complications / epidemiology Prospective Studies Ventricular Dysfunction, Left / epidemiology |
| Chemical | |
Reg. No./Substance:
|
114471-18-0/Natriuretic Peptide, Brain |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Characteristics of new cardiac surgery programs in the United States: Mitigating the learning curve.
Next Document: Enzyme replacement therapy for Fabry's disease.